Anthem Blue Cross and Blue Shield in Indiana names new president
Anthem Blue Cross and Blue Shield in Indiana has appointed Beth Keyser as its new president. Keyser, a seasoned healthcare executive with over 25 years of experience, will lead the company's health plan operations in Indiana, focusing on improving healthcare access and outcomes for members. Her appointment is expected to drive the company's efforts in strengthening community partnerships and innovating healthcare solutions within the state.
The US$7bn Shift: Elevance Health’s Supply Chain
Elevance Health is leveraging AI and a sustainable US$7bn supply chain to drive its digital transformation and achieve net-zero goals, redefining healthcare delivery. The company emphasizes the critical importance of reliable and sustainable supply chains in healthcare, integrating AI and data analytics to improve care. Elevance Health's approach requires supply chain partners to support ambitious sustainability and digital innovation goals, with a strong focus on ESG compliance and collaborative innovation.
Amanda Free Named President, Anthem Blue Cross and Blue Shield of Georgia
Amanda Free has been appointed as the new President of Anthem Blue Cross and Blue Shield of Georgia. She brings over 20 years of experience in sales, operations, and consulting, having previously served as Vice President of Local Operations for Anthem's Commercial Health Benefits division and held leadership roles at Humana. Free will focus on advancing affordability, access, and whole health solutions for members and employer partners across Georgia.
Jessica Lopez-Liggett Named President of Anthem Blue Cross and Blue Shield in Indiana
Jessica Lopez-Liggett has been appointed Commercial State Plan President of Anthem Blue Cross and Blue Shield in Indiana, succeeding Beth Keyser. Lopez-Liggett, a 20-year healthcare industry veteran, previously served as Regional Vice President of Sales for Anthem in Indiana, where she focused on market strategy, partnerships, and growth. She will continue to lead efforts in improving healthcare affordability, simplifying the system, and enhancing whole health for Hoosiers.
Weight Management Supplements Market Report 2026: A $15+ Billion Market by 2030 Featuring Leading Players - Nestle, Abbott Laboratories, GSK, Glanbia, Herbalife Nutrition, and Amway - Forecast to 2035
The weight management supplements market is experiencing significant growth, projected to reach $15.08 billion by 2030 from $7.88 billion in 2026, driven by factors like increasing obesity rates, consumer focus on wellness, and personalized nutrition demand. Key trends include plant-based and botanical supplements, digital health integration, and online sales. Leading companies such as Nestle, Abbott, and Herbalife Nutrition are innovating with new products and strategic acquisitions to capitalize on market opportunities globally.
How Elevance Health Brings Sustainability into Healthcare
Elevance Health is committed to transforming healthcare delivery by integrating digital innovation and sustainability initiatives. The company aims for net-zero greenhouse gas emissions by 2030 and prioritizes renewable energy, while also using AI and data analytics to personalize care. Furthermore, Elevance Health emphasizes supply chain sustainability, requiring suppliers to meet ESG standards to strengthen operations and promote environmental stewardship.
UnitedHealth stock edges up near $290 as Medicare Advantage shakeout returns to spotlight
UnitedHealth (UNH) stock edged up by 0.5% to $289.57, performing better than the general U.S. market, as the challenges within the Medicare Advantage program are highlighted. A recent study revealed that nearly 3 million Medicare Advantage members were forced to switch plans for 2026 due to insurers exiting markets or reducing options, with UnitedHealthcare accounting for a significant portion of these changes. Investors are closely monitoring the Centers for Medicare & Medicaid Services' (CMS) upcoming decisions on 2027 Medicare Advantage payment rates, alongside ongoing concerns about medical costs and cybersecurity risks affecting UnitedHealth's Change Healthcare unit.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elevance Health, Inc. (ELV) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elevance Health, Inc. (ELV) securities. The investigation focuses on whether Elevance and its officers engaged in corporate wrongdoing, specifically for investors who bought shares before April 18, 2024, and still hold them. The firm encourages affected investors to contact them to assist with the investigation, which is conducted on a contingency fee basis.
New Haven sues Cigna, CVS Health, UnitedHealth over insulin pricing scheme
The City of New Haven has filed a RICO lawsuit against Cigna, CVS Health, UnitedHealth, and three insulin manufacturers, alleging a scheme to artificially inflate insulin prices between 2010 and 2019. The lawsuit claims that manufacturers set high list prices and funneled secret rebates and administrative fees to Pharmacy Benefit Managers (PBMs) in exchange for preferred formulary placement, leading to inflated costs for self-insured health plans. New Haven is seeking treble damages, disgorgement, punitive damages, and injunctive relief, claiming violations of federal and state antitrust and unfair trade practices acts.
Centene Stock Just Shocked Wall Street – Here’s What You Need to Know
Centene Corp. (CNC) has released new earnings and guidance that impact the health insurance market, especially for Medicaid and ACA plans. The company is focusing on improving profit margins, stabilizing membership amid Medicaid redeterminations, and cleaning up its portfolio by exiting lower-margin businesses. This strategy could lead to tighter networks and increased digital tools for consumers, while investors are watching for consistent earnings growth and the company's ability to manage medical costs and policy shifts.
Is Wall Street Bullish or Bearish on Elevance Stock?
Elevance Health (ELV) has underperformed the broader market and healthcare peers, with its stock declining over the past year. Despite this, analysts have a "Moderate Buy" rating, with 12 "Strong Buy" and nine "Hold" recommendations, a more bullish sentiment than two months prior. The company's Q4 2025 earnings beat expectations, and analysts project a significant upside potential for the stock.
Insiders At Elevance Health Sold US$3.5m In Stock, Alluding To Potential Weakness
Insiders at Elevance Health have sold US$3.5 million worth of stock over the past year, although there was also US$2.8 million in insider buying. While a significant insider purchase by the President for US$2.1 million was made at a lower price point, the overall trend of more selling than buying at current valuations raises questions. Despite this, insiders still own 0.1% of the company, valued at US$78 million, suggesting some alignment with shareholder interests.
Is Elevance Health Quietly Becoming a Defensive Growth Stock for 2026?
Elevance Health (NYSE: ELV) continues to deliver strong financial results, beating earnings expectations and reaffirming its full-year outlook, yet it remains relatively overlooked by many US investors. The company is characterized as a defensive compounder due to its stable earnings, disciplined cost management, and robust capital return strategy through share repurchases and dividends. Despite potential risks related to policy changes and medical cost trends, Wall Street analysts maintain a constructive view, positioning ELV as a compelling option for long-term investors seeking both growth and portfolio defense.
1 Profitable Stock to Target This Week and 2 We Avoid
This article identifies one profitable stock, Elevance Health (ELV), as a company to target due to its consistent revenue growth, large revenue base, and strong return on capital. Conversely, it advises avoiding Fastenal (FAST) and Bio-Techne (TECH) due to their muted revenue and earnings growth, high valuations, and in Bio-Techne's case, subscale operations and shrinking free cash flow margin. The analysis emphasizes looking beyond profitability to growth and operational efficiency when evaluating investment opportunities.
Lifeward's ReWalk Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
Lifeward's ReWalk Personal Exoskeleton is now covered by Aetna, joining Humana and UnitedHealthcare to provide Medicare Advantage coverage for eligible beneficiaries with spinal cord injuries. This expansion means that three of the largest Medicare Advantage insurers collectively cover approximately 16 million beneficiaries across the U.S. The decision reinforces the ReWalk system as a medically necessary and appropriate therapeutic intervention, as validated by independent reviews of clinical evidence.
The UnitedHealth Reset: Analyzing the 3.1% Surge and the Future of the Dow’s Healthcare Titan
UnitedHealth Group (UNH) experienced a 3.1% surge on February 13, 2026, offering a glimmer of hope after a significant stock decline earlier in the year. This report examines whether this rally signifies a definitive bottom for the healthcare giant or if regulatory and operational challenges in 2026 will persist. The article details UNH's business model, financial performance, leadership changes, and the competitive landscape, concluding that 2026 is a "Reset Year" for the company amid intensified scrutiny and lower government reimbursements.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by Elevance Health, Inc. (ELV). The firm is encouraging investors who purchased Elevance securities before April 18, 2024, and still hold them, to come forward and assist in the investigation. The firm operates on a contingency fee basis, meaning there is no upfront cost for investors to participate.
UBS Lowered Firm’s PT on Elevance Health (ELV), Kept a Buy Rating
UBS has re-evaluated its price target for Elevance Health (ELV), decreasing it while maintaining a "Buy" rating on the stock. This adjustment reflects a modified outlook for the company's valuation, despite continued analyst confidence in its overall performance and future prospects.
Coronation Fund Managers Ltd. Sells 9,872 Shares of Elevance Health, Inc. $ELV
Coronation Fund Managers Ltd. has reduced its stake in Elevance Health (NYSE:ELV) by 7.2%, selling 9,872 shares to hold 127,495 shares valued at $41.2 million. This position represents 2.1% of Coronation's portfolio. The article also notes mixed analyst sentiments, with Zacks lowering some near-term EPS estimates while raising a Q4 2027 forecast, and MarketBeat's consensus being a "Moderate Buy" with an average target price of $390.55.
Coronation Fund Managers Ltd. Raises Stake in HDFC Bank Limited $HDB
Coronation Fund Managers Ltd. significantly increased its stake in HDFC Bank Limited by 139.8% during the third quarter, now owning 70,653 shares valued at over $2.4 million. Several other institutional investors like Robeco and C WorldWide also substantially boosted their positions, indicating strong institutional confidence in the bank, which now has approximately 17.61% institutional ownership. Despite some analysts moving towards a "Hold" rating, HDFC Bank recently surpassed quarterly EPS estimates and maintains a market capitalization near $165.7 billion.
Cibc World Market Inc. Has $6.40 Million Stock Holdings in Elevance Health, Inc. $ELV
Cibc World Market Inc. increased its stake in Elevance Health ($ELV) by 24.4% in Q3, now holding 19,807 shares valued at $6.40 million. Elevance Health recently declared a quarterly dividend increase to $1.72 per share and reported Q4 earnings that beat analyst estimates. The company also received a "Moderate Buy" rating from analysts with an average price target of $390.55.
Caprock Group LLC Acquires New Position in Elevance Health, Inc. $ELV
Caprock Group LLC has acquired a new position in Elevance Health, Inc. (NYSE:ELV), purchasing 5,140 shares valued at approximately $1.64 million, as institutional investors now hold around 89.24% of the stock. Elevance Health reported better-than-expected Q3 earnings per share of $3.33, though revenue slightly missed consensus, and the company increased its quarterly dividend. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $390.55, despite some recent downgrades and target price trims.
Assetmark Inc. Acquires 19,078 Shares of Elevance Health, Inc. $ELV
Assetmark Inc. significantly increased its stake in Elevance Health (NYSE:ELV) by 28.2% in the third quarter, acquiring an additional 19,078 shares to hold a total of 86,775 shares valued at $28.04 million. Despite mixed analyst sentiment and some firms trimming price targets, Elevance Health reported a quarterly EPS beat, strong revenue growth, and raised its quarterly dividend, signaling continued financial stability. Other institutional investors also adjusted their positions, indicating varied confidence in the healthcare giant.
AG Paxton seeks information for BCBS; Conduent data breach
Texas Attorney General Ken Paxton has launched an investigation into a major data breach affecting Blue Cross Blue Shield of Texas (BCBS) and Conduent Business Services, LLC. The breach, which Conduent described as a "cyber incident" that occurred last year, potentially exposed the personal and health insurance information of approximately four million Texans, including Medicaid recipients. Paxton's office has issued Civil Investigative Demands to both companies, seeking documents and information to determine compliance with state laws and to prevent future breaches.
Public Sector Pension Investment Board Has $34.47 Million Stock Holdings in Elevance Health, Inc. $ELV
Public Sector Pension Investment Board significantly increased its stake in Elevance Health, Inc. (NYSE:ELV) by 515.5% in the third quarter, bringing their total holdings to 106,682 shares valued at $34.47 million. Several other hedge funds also adjusted their positions in ELV. The article also provides an overview of recent analyst ratings, company performance metrics, and dividend information for Elevance Health.
Oppenheimer Asset Management Inc. Trims Stake in Elevance Health, Inc. $ELV
Oppenheimer Asset Management Inc. significantly reduced its stake in Elevance Health, Inc. ($ELV) by 62.2% in the third quarter, selling 10,300 shares and retaining 6,247 shares valued at approximately $2.02 million. This comes as Elevance Health reported strong Q3 earnings, beating EPS expectations and showing 9.6% revenue growth, leading them to raise their quarterly dividend and set FY2026 EPS guidance. Despite mixed analyst ratings, the stock holds a "Moderate Buy" consensus target price of $390.55, with institutional investors owning a substantial 89.24% of the company.
American Well (AMWL) Q4 2025 Earnings Transcript
American Well (AMWL) reported Q4 2025 earnings, highlighting a strategic pivot from a multi-product telehealth provider to an exclusively tech platform business focused on SaaS-based revenue streams. The company saw a 22.1% year-over-year revenue decline to $55.3 million but improved its adjusted EBITDA loss to $10.3 million. Management expressed confidence in achieving positive cash flow from operations by Q4 2026, driven by significant cost reductions, major payer contract renewals, and a strong focus on government opportunities and AI integration within its platform.
Madison Asset Management LLC Decreases Holdings in Elevance Health, Inc. $ELV
Madison Asset Management LLC significantly reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 88.4% in the third quarter, selling 126,753 shares and retaining 16,600 shares valued at $5.36 million. Despite this, other institutional investors have made smaller adjustments to their positions, and 89.24% of the stock is held by hedge funds and institutional investors. The article also provides an overview of recent analyst ratings, stock performance metrics, dividend information, and key news impacting Elevance Health, including some upward revisions to future EPS estimates by Zacks but also notable cuts to near-term forecasts and a House Judiciary probe investigation.
2 Reasons to Like ELV (and 1 Not So Much)
Elevance Health (NYSE:ELV) has shown strong market performance, aligning with the S&P 500, and possesses significant advantages like economies of scale and a stellar return on invested capital (ROIC) of 27.2%. However, the company faces a challenge with a declining customer base, averaging 1.2% year-on-year declines over the past two years, signaling potential product weakness, increased competition, or market saturation. Despite this, the article concludes that its merits generally outweigh its flaws, but encourages investors to review a comprehensive report to determine if it's the right time to buy.
5 Revealing Analyst Questions From SS&C's Q4 Earnings Call
This article highlights key analyst questions from SS&C Technologies Holdings Inc.'s Q4 earnings call, focusing on areas like healthcare segment growth, the Elevance relationship, alternative fund administration, intelligent automation, and wealth/investment management prospects. It also outlines the company's strong Q4 results, surpassing revenue and EPS estimates, and discusses future catalysts.
Humana's Q4 loss widens
Humana reported a wider net loss in Q4 and projected a significant decline in its 2026 EPS, primarily due to a headwind from Medicare Advantage (MA) Star Ratings. Despite this, the company anticipates approximately 25% individual MA membership growth in 2026. Humana is more exposed to MA-specific shocks than diversified rivals due to its MA-heavy business mix, though expansions in care delivery and Medicaid platforms are adding some diversification.
Wealthfront Advisers LLC Buys 19,292 Shares of Elevance Health, Inc. $ELV
Wealthfront Advisers LLC significantly increased its stake in Elevance Health (NYSE:ELV) by 122.5%, adding 19,292 shares to now own 35,042 shares valued at approximately $11.323 million. This comes as Elevance Health reported strong quarterly earnings, beating EPS expectations, and increased its quarterly dividend. Analysts currently rate the stock as a "Moderate Buy" with an average price target of $390.55.
Elevance Health Q3 EPS Forecast Decreased by Zacks Research
Zacks Research has decreased its Q3 2026 EPS forecast for Elevance Health (NYSE:ELV) to $5.41 from $5.68, maintaining a "Hold" rating. Despite this, the company recently reported Q3 EPS of $3.33, beating estimates, and revenue of $49.31 billion, slightly missing expectations. Analysts have a "Moderate Buy" consensus rating with a target price of $390.55, and Elevance Health also increased its quarterly dividend to $1.72.
Investment Management Associates Inc. ADV Takes Position in Elevance Health, Inc. $ELV
Investment Management Associates Inc. ADV initiated a new position in Elevance Health, Inc. (NYSE:ELV) during Q3, acquiring 13,108 shares valued at approximately $4.235 million, representing 1.2% of their portfolio. Elevance Health surpassed Q3 earnings expectations with $3.33 EPS and reported strong revenue growth, leading to a "Moderate Buy" consensus rating and a target price of $390.55 from Wall Street analysts. The company also increased its quarterly dividend to $1.72 per share, offering an annualized yield of around 2.1%.
Advisors Asset Management Inc. Boosts Holdings in Elevance Health, Inc. $ELV
Advisors Asset Management Inc. significantly increased its stake in Elevance Health, Inc. by 16.9% in Q3, now holding 35,545 shares valued at $11.49 million, contributing to an overall institutional ownership of approximately 89.24%. Elevance Health reported strong Q3 earnings, beating EPS estimates while revenue slightly missed, and has a consensus "Moderate Buy" rating with a target price of $390.55. The company also raised its quarterly dividend to $1.72 per share, reflecting a 2.1% yield.
Humana Earnings Preview: Waiting for More on Medicare Advantage
Humana is scheduled to report its fourth-quarter earnings on Wednesday. The earnings call comes as Humana and other insurers are dealing with proposed Medicare Advantage payment rates, which have recently caused a market selloff. Investors will be looking for more insights into the future prospects of Medicare Advantage.
CVS annual profit guidance misses Wall Street estimates
CVS Health Corp. has missed Wall Street's profit projections for 2026, forecasting adjusted earnings of $7 to $7.20 a share, which is below the average analyst estimate. The company also lowered its cash flow from operations estimate to at least $9 billion, down from $10 billion. This cautious outlook comes amidst industry tumult and increased scrutiny from lawmakers regarding healthcare costs, particularly impacting its Medicare Advantage business.
Candriam S.C.A. Trims Stake in Elevance Health, Inc. $ELV
Candriam S.C.A. reduced its stake in Elevance Health (NYSE:ELV) by 27% in Q3 2025, selling 18,211 shares, though its remaining 49,258 shares are valued at $15.9 million. Elevance Health reported strong Q3 earnings, beating analyst EPS estimates, and increased its quarterly dividend. The company maintains a "Moderate Buy" consensus rating from analysts.
Republican-led US House panel issues subpoenas to eight health insurers, Axios reports
A Republican-led US House panel has issued subpoenas to eight Affordable Care Act health insurers as part of an expanding investigation into potential fraud concerning the use of premium subsidies, Axios reported. The subpoenas, issued by House Judiciary Chair Jim Jordan, demand documents related to subsidized ACA enrollees and discussions on subsidy-related fraud, with a deadline of February 23. This action follows previous requests in December triggered by federal auditors detecting subsidized coverage for non-existent individuals and other fraud risks.
SVB Wealth LLC Sells 4,116 Shares of Elevance Health, Inc. $ELV
SVB Wealth LLC reduced its stake in Elevance Health, Inc. by 19.7% in the third quarter, selling 4,116 shares and leaving them with 16,749 shares valued at $5.41 million. Despite this, other institutional investors increased their holdings in ELV. Elevance Health (NYSE:ELV) reported strong quarterly earnings, beating EPS estimates, and raised its quarterly dividend, while analysts maintain a "Moderate Buy" consensus with an average price target of $390.55.
Is Elevance Health (ELV) Trading at an Attractive Valuation?
Sequoia Strategy, managed by Ruane, Cunniff LP, released its Q4 2025 investor letter, highlighting its outperformance against the S&P 500 Index. The letter discussed its opportunistic investments in managed care companies like Elevance Health, Inc. (NYSE: ELV) and UnitedHealth Group Inc. and its decision to reduce holdings in 2022 due to high valuations. Despite Elevance Health's Q4 2025 revenue increase, Sequoia Strategy suggests a greater conviction in AI stocks for higher, quicker returns.
Here’s What Happened to UnitedHealth Group (UNH)
The article discusses UnitedHealth Group (UNH) performance according to Ruane, Cunniff LP's Q4 2025 investor letter. While the Sequoia Strategy fund returned 21.9% in 2025, beating the S&P 500, UnitedHealth Group detracted from the fund's Q4 performance due to significant stock price declines. The letter explains the strategy behind their investment in UNH and Elevance Health, initiated due to market fears and later partially sold off due to high valuations.
The Future of a Healthcare Titan: UnitedHealth Group (UNH) at a Regulatory Crossroads
UnitedHealth Group (UNH) is at a critical juncture in early 2026, transitioning from growth to consolidation amidst intense federal scrutiny, particularly concerning its Medicare Advantage practices. The company, under returning CEO Stephen Hemsley, aims for financial rigor, operational discipline, and significant AI implementation to navigate regulatory challenges and maintain industry leadership. Its integrated "Payer-Provider" model, especially through its Optum segment, is central to its strategy but also a target of regulatory oversight.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elevance Health, Inc. (ELV) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Elevance Health, Inc. (NYSE:ELV). The firm encourages stockholders who purchased Elevance securities before April 18, 2024, and still hold them, to contact them to assist in the investigation. The investigation aims to determine if Elevance and its officers/directors engaged in improper activities.
TenCore Partners LP Invests $11.31 Million in Elevance Health, Inc. $ELV
TenCore Partners LP recently acquired a new stake of 35,000 shares in Elevance Health, Inc. (NYSE:ELV), valued at approximately $11.31 million, making it their 7th largest holding. This investment comes as Elevance Health reported strong quarterly earnings, beating EPS estimates, and raised its quarterly dividend, while analysts maintain a "Moderate Buy" rating with a consensus price target of $390.55. Other institutional investors have also adjusted their holdings in the healthcare company.
Elevance Health, Inc. $ELV Shares Purchased by Bessemer Group Inc.
Bessemer Group Inc. significantly increased its stake in Elevance Health (NYSE: ELV) by 5.9% in Q3, now holding 147,372 shares valued at approximately $47.62 million. Institutional investors collectively own about 89.24% of the stock. Elevance Health reported strong Q3 earnings, beating EPS estimates, and raised its quarterly dividend to $1.72, signaling confidence in its financial performance.
Ensign Group Q4 Earnings Beat Estimates on Growing Occupancy
The Ensign Group (ENSG) reported strong fourth-quarter 2025 adjusted earnings per share of $1.82, exceeding estimates by 4% and increasing 19.5% year-over-year. Operating revenues grew 20.2% to $1.36 billion. This growth was primarily driven by improved occupancy rates, higher patient days, and strong skilled service performance, despite higher expenses. The company also provided a positive outlook for 2026, forecasting revenues between $5.77 billion and $5.84 billion and adjusted EPS between $7.41 and $7.61.
Will Declining Medical Membership Affect Humana's Q4 Earnings?
Humana (HUM) is poised to release its Q4 2025 earnings on February 11, with analysts projecting a loss of $4.01 per share on $31.9 billion in revenues, despite an anticipated 9.2% year-over-year revenue growth. The company's Earnings ESP of 0.00% and a Zacks Rank #4 (Sell) suggest it may not beat earnings expectations. Key factors influencing results include an expected rise in total operating costs and a forecasted 7.6% decline in medical membership, potentially leading to a decrease in the bottom line.
Elevance Health, Inc. SEC 10-K Report
Elevance Health, Inc. has released its annual Form 10-K report, providing insights into its financial and operational performance for the fiscal year ended December 31, 2025. The report details the company's revenue segments, including Health Benefits and CarelonRx, its geographical presence as a Blue Cross licensee, and its strategic initiatives such as portfolio rationalization and expansion into new markets. It also highlights challenges and risks like healthcare cost management, cybersecurity, and regulatory changes, outlining the company's efforts to address these through enhanced security, cost optimization, and technological advancements.
Will Declining Medical Membership Affect Humana's Q4 Earnings?
Humana Inc. is scheduled to report its fourth-quarter 2025 earnings on February 11, 2026, with analysts projecting a loss of $4.01 per share on revenues of $31.9 billion. Despite anticipated revenue growth, the company's profitability is expected to be impacted by a projected increase in operating costs and a decline in medical membership. The article also reviews the recent performance of competitors like The Cigna Group, UnitedHealth Group, and Elevance Health.
